Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence

<div>The meta-analysis results of afatinib efficacy and safety in advanced NSCLC with EGFR mutation: (a) the outcome of disease control rates (DCRs) and (b) the outcome of objective response rates (ORRs).</div>

Journal of Oncology

fig2

Figure 2

Figure 2: Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence 

Figure 2 | Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence 